Journal of Clinical Oncology, Vol 16, 405-410, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

PG Rose, JA Blessing, AR Mayer and HD Homesley
Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Case Western Reserve University, OH, USA.

PURPOSE: A phase II trial was conducted to determine the activity of prolonged oral etoposide in platinum-resistant and platinum-sensitive ovarian carcinoma. PATIENTS AND METHODS: Platinum-resistant disease was defined as progression on platinum-based chemotherapy or recurrence within 6 months of completing therapy. The starting dose was 50 mg/m2/d (30 mg/m2/d for prior radiotherapy) for 21 days, every 28 days. A dose escalation to a maximum dose of 60 mg/m2/d was prescribed. RESULTS: Of 99 patients entered, 97 were assessable for toxicity and 82 were assessable for response. Among 41 platinum-resistant patients a 26.8% response rate (7.3% complete response [CR] and 19.5% partial response [PR] rate) occurred. The median response duration was 4.3 months (range, 1.3 to 8.7), median progression-free interval (PFI) was 5.7 months (range, 0.8 to 30.8+), and median survival time was 10.8 months (range, 1.9 to 45.8). Twenty-five of 41 platinum-resistant patients had also previously received paclitaxel; of which eight (32%) responded. Among 41 platinum-sensitive patients, a 34.1% response rate (14.6% CR and 19.5% PR rate) occurred. The median response duration was 7.5 months (range, 1.9 to 15.2+), median PFI was 6.3+ months (range, 0.9 to 20.4), and median survival time was 16.5+ months (range, 0.9 to 34.8). Of 97 patients assessable for toxicity, grade 3 or 4 hematologic toxicity was common, with leukopenia occurring in 41.2% (grade 3, 29%; grade 4, 12%), neutropenia in 45.4% (grade 3, 20%; grade 4, 25%), thrombocytopenia in 9% (grade 3, 5%; grade 4, 4%), and anemia in 13.4%. Three treatment-related deaths occurred: two from neutropenic sepsis and one from thrombocytopenic bleeding after an overdose. One patient developed leukemia. CONCLUSION: This regimen is active in platinum- resistant and platinum-sensitive ovarian carcinoma. Additionally, the regimen is active in paclitaxel-resistant ovarian carcinoma.

This article has been cited by other articles:

				M. Markman New, Expanded, and Modified Use of Approved Antineoplastic Agents in Ovarian Cancer Oncologist, February 1, 2007; 12(2): 186 - 190. [Abstract] [Full Text] [PDF]

				T. Ohta, M. Ohmichi, T. Hayasaka, S. Mabuchi, M. Saitoh, J. Kawagoe, K. Takahashi, H. Igarashi, B. Du, M. Doshida, et al. Inhibition of Phosphatidylinositol 3-Kinase Increases Efficacy of Cisplatin in in Vivo Ovarian Cancer Models Endocrinology, April 1, 2006; 147(4): 1761 - 1769. [Abstract] [Full Text] [PDF]

				S. Campos, O. Hamid, M. V. Seiden, A. Oza, M. Plante, R. K. Potkul, P. F. Lenehan, E. P. Kaldjian, M. L. Varterasian, C. Jordan, et al. Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer J. Clin. Oncol., August 20, 2005; 23(24): 5597 - 5604. [Abstract] [Full Text] [PDF]

				H. S Sano, J A. Waddell, D. A Solimando Jr, P. Doulaveris, and R. Myhand Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost Journal of Oncology Pharmacy Practice, March 1, 2005; 11(1): 21 - 30. [Abstract] [PDF]

				P. G. Rose Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer Oncologist, March 1, 2005; 10(3): 205 - 214. [Abstract] [Full Text] [PDF]

				T. J. Herzog Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression? Clin. Cancer Res., November 15, 2004; 10(22): 7439 - 7449. [Abstract] [Full Text] [PDF]

				G. Aravantinos, D. Bafaloukos, G. Fountzilas, C. Christodoulou, C. Papadimitriou, N. Pavlidis, H. P. Kalofonos, H. Gogas, P. Kosmidis, and M. A. Dimopoulos Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer Ann. Onc., July 1, 2003; 14(7): 1094 - 1099. [Abstract] [Full Text] [PDF]

				M. A. Bookman Developmental Chemotherapy and Management of Recurrent Ovarian Cancer J. Clin. Oncol., May 15, 2003; 21(90100): 149s - 167. [Abstract] [Full Text] [PDF]

				M.-C. Le Deley, T. Leblanc, A. Shamsaldin, M.-A. Raquin, B. Lacour, D. Sommelet, A. Chompret, J.-M. Cayuela, C. Bayle, A. Bernheim, et al. Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Societe Francaise d'Oncologie Pediatrique J. Clin. Oncol., March 15, 2003; 21(6): 1074 - 1081. [Abstract] [Full Text] [PDF]

				T. J. Herzog Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer Oncologist, October 1, 2002; 7(90005): 3 - 10. [Abstract] [Full Text] [PDF]

				C. J. Dunton Management of Treatment-Related Toxicity in Advanced Ovarian Cancer Oncologist, October 1, 2002; 7(90005): 11 - 19. [Abstract] [Full Text] [PDF]

				D. K. Armstrong Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease Oncologist, October 1, 2002; 7(90005): 20 - 28. [Abstract] [Full Text] [PDF]

				R. F. Ozols Recurrent Ovarian Cancer: Evidence-Based Treatment J. Clin. Oncol., March 1, 2002; 20(5): 1161 - 1163. [Full Text] [PDF]

				D. S. Dizon, M. L. Hensley, E. A. Poynor, P. Sabbatini, C. Aghajanian, A. Hummer, E. Venkatraman, and D. R. Spriggs Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian Cancer J. Clin. Oncol., March 1, 2002; 20(5): 1238 - 1247. [Abstract] [Full Text] [PDF]

				A. N. Gordon, J. T. Fleagle, D. Guthrie, D. E. Parkin, M. E. Gore, and A. J. Lacave Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan J. Clin. Oncol., July 15, 2001; 19(14): 3312 - 3322. [Abstract] [Full Text] [PDF]

				A. N. Gordon, C. O. Granai, P. G. Rose, J. Hainsworth, A. Lopez, C. Weissman, R. Rosales, and T. Sharpington Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer J. Clin. Oncol., September 17, 2000; 18(17): 3093 - 3100. [Abstract] [Full Text] [PDF]

				P. G. Rose, M. Rodriguez, S. Waggoner, B. E. Greer, I. R. Horowitz, J. M. Fowler, and W. P. McGuire Phase I Study of Paclitaxel, Carboplatin, and Increasing Days of Prolonged Oral Etoposide in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study J. Clin. Oncol., August 16, 2000; 18(16): 2957 - 2962. [Abstract] [Full Text] [PDF]

				M. Seiden Highlights in Ovarian Cancer Oncologist, August 1, 2000; 5(4): 267 - 273. [Abstract] [Full Text]

				G. Toffoli, R. Sorio, P. Aita, D. Crivellari, G. Corona, A. Bearz, I. Robieux, A. M. Colussi, F. Stocco, and M. Boiocchi Dose-finding and Pharmacologic Study of Chronic Oral Idarubicin Therapy in Metastatic Breast Cancer Patients Clin. Cancer Res., June 1, 2000; 6(6): 2279 - 2287. [Abstract] [Full Text]

				M. J. Piccart, J. A. Green, A. J. Lacave, N. Reed, I. Vergote, P. Benedetti-Panici, A. Bonetti, V. Kristeller-Tome, C. M. Fernandez, D. Curran, et al. Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group J. Clin. Oncol., March 13, 2000; 18(6): 1193 - 1202. [Abstract] [Full Text] [PDF]

				M. Markman and M. A. Bookman Second-Line Treatment of Ovarian Cancer Oncologist, February 1, 2000; 5(1): 26 - 35. [Abstract] [Full Text]

				J. E. Groopman and L. M. Itri Chemotherapy-Induced Anemia in Adults: Incidence and Treatment J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634. [Abstract] [Full Text] [PDF]

				M. A. Bookman Extending the Platinum-Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second-Line Chemotherapy Oncologist, April 1, 1999; 4(2): 87 - 94. [Abstract] [Full Text]

				S. A. Cannistra Back to the Future: Multiagent Chemotherapy in Ovarian Cancer Revisited J. Clin. Oncol., March 1, 1999; 17(3): 741 - 741. [Full Text] [PDF]